ISSN: 1859 - 2872
Measuring the serum concentration of 10 cytokines in early-stage systemic sclerosis patients
Main Article Content
Keywords
Abstract
Objective: To measure the serum concentration of cytokines in systemic sclerosis patients (SSc) and to evaluate the relationship between cytokine concentration and clinical presentation. Subject and method: A cross-sectional study was conducted in early-stage SSc patients, evaluating clinical presentation and measuring serum concentration of 7 cytokines: TNF, MCP-1, TGF-β1, IL-6, BAFF, IL-10, and IL-2. Result: 32 patients (21 diffuse SSc, 11 limited SSc) were recruited. MCP-1, TGF-β1, IL-6, and BAFF were detected in almost all patients, other cytokines were detected in 31.3% - 40.6% of the patients, with low concentration. There was no relationship between the concentration of these cytokines and severe skin thickening, pulmonary arterial hypertension, difficulty swallowing, abnormal urinalysis, and muscle injury. IL-10 above detection threshold was associated with digital ulcer. MCP-1 ≥ 389.2pg/ml and IL-10 above detection threshold were associated with severe interstitial lung disease and joint pain. Conclusion: Measuring the serum concentration of cytokines can help clarify the pathogenesis and suggest effective novel therapies for SSc.
Article Details
References
2. Hasegawa M, Fujimoto M, Matsushita T et al (2011) Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 30(2): 231-237.
3. Antonelli A, Ferri C, Fallahi P et al (2008) CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 47(1): 45-49.
4. Matsushita T, Hasegawa M, Hamaguchi Y et al (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33(2): 275-284.
5. Scolnik M, Catoggio LJ, Lancioni E et al (2014) Are there clinical differences in limited systemic sclerosis according to extension of skin involvement? Int J Rheumatol 716358.
6. Lafyatis R (2014) Transforming growth factor beta-at the centre of systemic sclerosis. Nat Rev Rheumatol 10(12): 706-719.
7. Khan K, Xu S, Nihtyanova S et al (2012) Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71(7): 1235-1242.
8. Matsushita T, Hasegawa M, Yanaba K et al (2006) Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54(1): 192-201.
9. Scala E, Pallotta S, Frezzolini A et al (2004) Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138(3): 540-546.
Article Sidebar
